4568
DAIICHI SANKYO COMPANY,LIMITED
第一三共
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Notes
- Stock adjustmentsOct 1, 2020 Stock split 1 share → 3 shares
Key metrics
Revenue(million JPY)
Mar 2021
962,516
Mar 2022
1,044,892
Mar 2023
1,278,478
Mar 2024
1,601,688
Mar 2025
1,886,256
Operating profit(million JPY)
Mar 2021
63,795
Mar 2022
73,025
Mar 2023
120,580
Mar 2024
211,588
Mar 2025
331,925
Operating profit margin(%)
Mar 2021
6.63
Mar 2022
6.99
Mar 2023
9.43
Mar 2024
13.21
Mar 2025
17.6
Profit before tax(million JPY)
Mar 2021
74,124
Mar 2022
73,516
Mar 2023
126,854
Mar 2024
237,234
Mar 2025
355,631
Profit(million JPY)
Mar 2021
75,958
Mar 2022
66,972
Mar 2023
109,188
Mar 2024
200,731
Mar 2025
295,756
Total assets(million JPY)
Mar 2021
2,085,178
Mar 2022
2,221,402
Mar 2023
2,508,889
Mar 2024
3,461,135
Mar 2025
3,456,119
Cash and cash equivalents(million JPY)
Mar 2021
380,547
Mar 2022
662,477
Mar 2023
441,921
Mar 2024
647,180
Mar 2025
639,838
Cash flows from operating activities(million JPY)
Mar 2021
192,207
Mar 2022
139,226
Mar 2023
114,514
Mar 2024
599,258
Mar 2025
53,842
Cash flows from investing activities(million JPY)
Mar 2021
-39,246
Mar 2022
212,339
Mar 2023
-257,782
Mar 2024
-282,636
Mar 2025
334,170
Cash flows from financing activities(million JPY)
Mar 2021
-202,433
Mar 2022
-86,231
Mar 2023
-89,594
Mar 2024
-123,564
Mar 2025
-377,769
Return on equity(%)
Mar 2021
5.9
Mar 2022
5.1
Mar 2023
7.8
Mar 2024
12.8
Mar 2025
17.9
Equity ratio(%)
Mar 2021
61
Mar 2022
60.8
Mar 2023
57.6
Mar 2024
48.8
Mar 2025
47
Earnings per share(JPY per share)
Mar 2021
39.17
Mar 2022
34.94
Mar 2023
56.96
Mar 2024
104.69
Mar 2025
155.96
Net assets per share(JPY per share)
Mar 2021
663.85
Mar 2022
704.76
Mar 2023
754.09
Mar 2024
880.4
Mar 2025
869.69
Dividend per share(JPY per share)
Mar 2021
27
Mar 2022
27
Mar 2023
30
Mar 2024
50
Mar 2025
60
Payout ratio(%)
Mar 2021
68.93
Mar 2022
77.28
Mar 2023
52.67
Mar 2024
47.76
Mar 2025
38.47
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.